AtherosclerosisNCT00005487
Multi-Ethnic Study of Atherosclerosis (MESA)
An observational study of Atherosclerosis and Cardiovascular Diseases, run by National Heart, Lung, and Blood Institute (NHLBI).
Trial summary
The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease (Bild DE et al., Am J Epidemiol 2002; 156(9):871-881). Read more about this study
- Who is it for?
- Ages 45 to 84 years
- Conditions the study is for
- Atherosclerosis, Cardiovascular Diseases, Heart Diseases
- How many people
- 6,418 participants
- Where
- No sites listed yet
- Study dates
- Jan 1999to Dec 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 84 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants were recruited from the MESA Study Field Centers.
CVD free men and women aged 45-84 at baseline from the four race/ethnic groups.
About this study
The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease (Bild DE et al., Am J Epidemiol 2002; 156(9):871-881). MESA consists of a diverse, community-based sample of an initial 6,814 men and women aged 45-84 years without known cardiovascular disease at baseline. Thirty-eight percent of the recruited participants were White, 28 percent African American, 22 percent Hispanic, and 12 percent of Chinese descent. Participants were recruited from six field centers across the United States: Baltimore City and Baltimore County, Maryland; Chicago, Illinois; Forsyth County, North Carolina; Los Angeles County, California; New York, New York; and St. Paul, Minnesota. Participants are being followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and heart failure; for cardiovascular disease interventions; and for mortality. The first examination took place over two years, from July 2000 to July 2002, and has been followed by additional examinations. Participants have been contacted every 9 to 12 months throughout the study to assess and adjudicate clinical morbidity and mortality. The study was approved by the Institutional review boards at all participating institutions, and all participants gave written informed consent. In addition, informed consent was obtained for extensive data sharing (dbGaP) and genetic/omic studies, including candidate genes (NHLBI CARe), genome-wide scans (NHLBI SHARe), exome sequencing (NHLBI ESP) and, most recently, the NHLBI TOPMed program.
Read the detailed description
Background:
MESA was derived from an NHLBI Task Force on Research in Epidemiology and Prevention in which investigation of subclinical disease and its progression to clinical disease was recommended as a major focus for future NHLBI population studies. This was followed by a Special Emphasis Panel on Longitudinal Cohort Studies in 1995, which strongly recommended studies based on subclinical disease measures, and the inclusion of underrepresented minorities in population-based research. A subsequent Special Emphasis Panel on Use of Cardiac EBCT and MRI in Epidemiologic Studies of Cardiovascular Disease in 1996 recommended inclusion of carotid and cardiac MRI and EBCT in elucidating the progression of subclinical to clinical disease and identifying subclinical disease characteristics most strongly associated with increased risk. Requests for Proposals were released in 1997 and awards were made in 1999.
Design Narrative:
Participants were examined at baseline for evidence of subclinical CVD using cardiac computed tomography (CT), cardiac MRI, carotid ultrasound, flow-mediated brachial artery dilation, radial artery tonometry, ankle-brachial index measurement; established and putative laboratory risk markers; and socioeconomic, psychological, behavioral, and environmental characteristics. Selected baseline components were repeated and additional components such as spirometry, retinal photography, genotyping, cognitive function assessment and, in subsets, abdominal aortic CT, carotid MRI, cardiac MRI tagging for measures of regional myocardial function, were introduced over five subsequent examinations through 2018. Stored blood samples have been assayed for putative biochemical risk factors and stored for case-control studies. DNA has been extracted for study of candidate genes, genome-wide scanning, expression, and other -omics investigations, and lymphocytes were cryopreserved for possible immortalization.
MESA is unique in its composition of four ethnic groups, having a cohort free of clinical CVD at baseline, and having multiple - and in some cases unique - subclinical CVD measures over time in the same individuals. Data collected from a large number and variety of MESA ancillary studies, including major ancillary studies on air pollution, chronic lung disease, genetics, and sleep, further contribute to its uniqueness. For a list of all phenotypic data documentation and protocols, refer to the MESA website: www.mesa-nhlbi.org. The MESA data are available to qualifying investigators directly from the study and also through dbGaP (http://www.ncbi.nlm.nih.gov/gap) and BioLINCC (https://biolincc.nhlbi.nih.gov). A variety of stored biospecimens are also available from the study, including DNA, serum, plasma, and urine.
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Coronary Disease, Stroke
- Keywords
- Coronary Arteriosclerosis, Cerebrovascular Accident, Heart Failure, Congestive, Diabetes Mellitus, Non-Insulin Dependent
- Medical subject headings
- Atherosclerosis, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Coronary Disease, Stroke, Myocardial Infarction, Heart Failure
What is being measured
The primary outcome is the main question the study is designed to answer.
CVD
Rate of Cardiovascular Disease
Measured: 06/18/2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2000 (estimated)
- Study startJan 1999
- Primary completionDec 2030 (estimated)
- Study completionDec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (81)Papers the sponsor has linked to this study.
- Other trials for AtherosclerosisStudies of the same condition, open and under way.
- More trials run by National Heart, Lung, and Blood Institute (NHLBI)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 6,418 participants (actual)
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
- Investigators
- Robyn McClelland, Principal investigator, University of WashingtonSteven Shea, Principal investigator, Columbia UniversityWendy Post, Principal investigator, Johns Hopkins UniversityNorrina Allen, Principal investigator, Northwestern UniversityKarol Watson, Principal investigator, University of California, Los AngelesJames Pankow, Principal investigator, University of MinnesotaNels Olson, Principal investigator, University of Vermont (biospecimen repository)Alain Bertoni, Principal investigator, Wake Forest University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00005487
- Sponsor's protocol ID
- 5003
- Status last verified
- Jun 2025
- First submitted
- 25 May 2000
- Last updated
- 21 Jan 2026
- Results posted
- No
Publications
Momtazmanesh S, Hathaway QA, Bancks MP, Bluemke DA, Barr RG, Post WS, Habes M, Nasrallah I, Heckbert SR, Bryan RN, Luchsinger JA, Wan M, Budoff M, Lima JAC, Hughes TM, Davatzikos C, Demehri S. Deep Learning-derived Bone Mineral Density and Longitudinal White Matter Microstructure and Cognitive Decline: Multi-Ethnic Study of Atherosclerosis. Radiology. 2026 Sep;320(3):e260656. doi: 10.1148/radiol.260656.
PubMed 42770818Hathaway QA, Ghotbi E, Pan T, Momtazmanesh S, Klein JG, Allison M, Barbosa EJM Jr, Barr RG, Bluemke DA, Lima JAC, Post W, Tison GH, Ambale-Venkatesh B, Budoff M, Demehri S. Opportunistic Chest CT Paraspinal Muscle Biomarkers to Predict Longitudinal Thoracic Vertebral Bone Mineral Density Loss: Results from MESA. Radiology. 2026 Sep;320(3):e260238. doi: 10.1148/radiol.260238.
PubMed 42742379Azimi A, Atlas K, Reeves AP, Zhang C, Wasserthal J, Mirjalili SR, Atlas T, Henschke CI, Yankelevitz DF, Zulueta JJ, Mechanick JI, Branch A, Ma N, Yip R, Fan W, Roy SK, Nasir K, Molloi S, Fayad ZA, McConnell MV, Kakadiaris IA, Abela GS, Vliegenthart R, Maron DJ, Narula J, Williams KA Sr, Shah PK, Budoff MJ, Levy D, Benjamin EJ, Wong ND, Naghavi M. AI-quantified Myosteatosis at CAC CT for Prediction of Atrial Fibrillation and Heart Failure: The Multi-Ethnic Study of Atherosclerosis. Radiol Cardiothorac Imaging. 2026 Aug;8(4):e250214. doi: 10.1148/ryct.250214.
PubMed 42390348Azimi A, Atlas K, Reeves AP, Zhang C, Wasserthal J, Mirjalili SR, Atlas T, Henschke CI, Yankelevitz DF, Zulueta JJ, de-Torres JP, Seijo LM, Mechanick JI, Branch A, Ma N, Yip R, Fan W, Roy SK, Nasir K, Molloi S, Fayad ZA, McConnell MV, Kakadiaris IA, Abela GS, Vliegenthart R, Maron DJ, Narula J, Williams KA, Shah PK, Budoff MJ, Levy D, Benjamin EJ, Mehran R, Kloner RA, Wong ND, Naghavi M. Artificial Intelligence-derived Measurements of Myosteatosis from Coronary Artery Calcium CT Scans to Predict COPD: The Multi-Ethnic Study of Atherosclerosis. Radiol Cardiothorac Imaging. 2026 Feb;8(1):e250205. doi: 10.1148/ryct.250205.
PubMed 41609478Ghotbi E, Hathaway QA, Bluemke DA, Ibad HA, Shabani M, Akhtarkhavari S, Barr RG, Post WS, Budoff M, Mathur A, Lima JAC, Demehri S. CT-derived Noncardiovascular Calcifications May Improve Coronary Heart Disease Prediction in Chronic Kidney Disease: The Multi-Ethnic Study of Atherosclerosis. Radiol Cardiothorac Imaging. 2025 Dec;7(6):e240546. doi: 10.1148/ryct.240546.
PubMed 41342680de Alencar JN, Felicioni SP. Electrocardiographic LVH criteria: Poor diagnostic accuracy even with optimized cutoffs. Insights from MESA study. J Electrocardiol. 2025 Nov-Dec;93:154138. doi: 10.1016/j.jelectrocard.2025.154138. Epub 2025 Sep 26.
PubMed 41027334Hoballah M, Chehab O, Abdollahi A, Wu CO, Scarpa B, Post WS, Allen NB, Bluemke DA, Ambale-Venkatesh B, Lima JAC. Left-to-Right Chamber Volume Ratios at Cardiac MRI Predict Cardiac Events: A Multi-Ethnic Study of Atherosclerosis Secondary Analysis. Radiology. 2025 Aug;316(2):e243462. doi: 10.1148/radiol.243462.
PubMed 40828040Hao QY, Gao JW, Zeng YH, Zhang SL, Xiong ZC, Li SC, Lin ZW, Yang PZ, Liu PM, Li ZH. Roles of triglyceride-glucose index in aortic valve calcification progression: a prospective and Mendelian randomization analysis. Clin Radiol. 2025 May;84:106860. doi: 10.1016/j.crad.2025.106860. Epub 2025 Feb 21.
PubMed 40106977Hathaway QA, Kasaeian A, Pan T, Bluemke DA, Ghotbi E, Klein JG, Ibad HA, Dailing C, Tison GH, Barr RG, Post W, Allison M, Lima JAC, Budoff M, Demehri S. A Deep Learning Model for Three-Dimensional Determination of Whole Thoracic Vertebral Bone Mineral Density from Noncontrast Chest CT: The Multi-Ethnic Study of Atherosclerosis. Radiology. 2025 Mar;314(3):e242133. doi: 10.1148/radiol.242133.
PubMed 40067103Chan JSK, Satti DI, Chan RNC, Chevli P, Mehta A, Martin SS, Sharma G, Tse G, Virani SS, Shapiro MD. Visit-to-visit lipid variability, coronary artery calcification, inflammation, and mortality in the Multi-Ethnic Study of Atherosclerosis. Eur J Prev Cardiol. 2025 Sep 22;32(13):1235-1244. doi: 10.1093/eurjpc/zwaf085.
PubMed 39977247Amiel PJ, Ambale-Venkatesh B, Wu CO, Matheson M, Ostovaneh MR, Lima JAC, Cox CF. Evaluating Incident Atrial Fibrillation and Incident Heart Failure as Time-varying Covariates for Time-to-Event Analysis Among Adults 55 Years and Older in the Multi-Ethnic Study of Atherosclerosis (MESA). J Card Fail. 2025 Dec;31(12):1809-1818. doi: 10.1016/j.cardfail.2025.01.012. Epub 2025 Feb 3.
PubMed 39909110Osmancevic A, Allison M, Miljkovic I, Vella CA, Ouyang P, Trimpou P, Daka B. Exploring the Relationships between Sex Hormones and Abdominal Muscle Area and Radiodensity in Postmenopausal Women: Insights from the Multi-Ethnic Study of Atherosclerosis. Maturitas. 2025 Mar;194:108197. doi: 10.1016/j.maturitas.2025.108197. Epub 2025 Jan 18.
PubMed 39827737Gao JW, Guo Q, Weng Y, Huang ZG, Zhang HF, Wu YB, Wang JF, Zhang SL, Liu PM. Predicting the risk of coronary artery calcium progression in the general population: insights from the MESA and CARDIA studies. Clin Radiol. 2025 Jan;80:106724. doi: 10.1016/j.crad.2024.10.006. Epub 2024 Oct 16.
PubMed 39546957Tang WHW, Lemaitre RN, Jensen PN, Wang M, Wang Z, Li XS, Nemet I, Lee Y, Lai HTM, de Oliveira Otto MC, Fretts AM, Sotoodehnia N, DiDonato JA, Backhed F, Psaty BM, Siscovick DS, Budoff MJ, Mozaffarian D, Hazen SL. Trimethylamine N-Oxide and Related Gut Microbe-Derived Metabolites and Incident Heart Failure Development in Community-Based Populations. Circ Heart Fail. 2024 Aug;17(8):e011569. doi: 10.1161/CIRCHEARTFAILURE.124.011569. Epub 2024 Aug 9.
PubMed 39119698Abdollahi A, Kato Y, Bakhshi H, Varadarajan V, Chehab O, Zeitoun R, Ostovaneh MR, Wu CO, Bertoni AG, Shah SJ, Ambale-Venkatesh B, Bluemke DA, Lima JAC. Differential Stroke Volume between Left and Right Ventricles as a Predictor of Clinical Outcomes: The MESA Study. Radiology. 2024 Jul;312(1):e232973. doi: 10.1148/radiol.232973.
PubMed 39041933
Study at a glance
From the registry record, last updated by the sponsor on 21 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multi-Ethnic Study of Atherosclerosis (MESA)
- ClinicalTrials.gov ID
- NCT00005487
- Acronym / sponsor ID
- 5003
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Coronary Disease, Stroke
- Keywords
- Coronary Arteriosclerosis, Cerebrovascular Accident, Heart Failure, Congestive, Diabetes Mellitus, Non-Insulin Dependent
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 6,418 participants (actual)
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)US National Institutes of Health
- Study start
- Jan 1999
- Primary completion
- Dec 2030 (estimated)
- Study completion
- Dec 2030 (estimated)
- First posted
- 26 May 2000 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease (Bild DE et al., Am J Epidemiol 2002; 156(9):871-881). MESA consists of a diverse, community-based sample of an initial 6,814 men and women aged 45-84 years without known cardiovascular disease at baseline. Thirty-eight percent of the recruited participants were White, 28 percent African American, 22 percent Hispanic, and 12 percent of Chinese descent. Participants were recruited from six field centers across the United States: Baltimore City and Baltimore County, Maryland; Chicago, Illinois; Forsyth County, North Carolina; Los Angeles County, California; New York, New York; and St. Paul, Minnesota. Participants are being followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and heart failure; for cardiovascular disease interventions; and for mortality. The first examination took place over two years, from July 2000 to July 2002, and has been followed by additional examinations. Participants have been contacted every 9 to 12 months throughout the study to assess and adjudicate clinical morbidity and mortality. The study was approved by the Institutional review boards at all participating institutions, and all participants gave written informed consent. In addition, informed consent was obtained for extensive data sharing (dbGaP) and genetic/omic studies, including candidate genes (NHLBI CARe), genome-wide scans (NHLBI SHARe), exome sequencing (NHLBI ESP) and, most recently, the NHLBI TOPMed program.
Detailed description
Background:
MESA was derived from an NHLBI Task Force on Research in Epidemiology and Prevention in which investigation of subclinical disease and its progression to clinical disease was recommended as a major focus for future NHLBI population studies. This was followed by a Special Emphasis Panel on Longitudinal Cohort Studies in 1995, which strongly recommended studies based on subclinical disease measures, and the inclusion of underrepresented minorities in population-based research. A subsequent Special Emphasis Panel on Use of Cardiac EBCT and MRI in Epidemiologic Studies of Cardiovascular Disease in 1996 recommended inclusion of carotid and cardiac MRI and EBCT in elucidating the progression of subclinical to clinical disease and identifying subclinical disease characteristics most strongly associated with increased risk. Requests for Proposals were released in 1997 and awards were made in 1999.
Design Narrative:
Participants were examined at baseline for evidence of subclinical CVD using cardiac computed tomography (CT), cardiac MRI, carotid ultrasound, flow-mediated brachial artery dilation, radial artery tonometry, ankle-brachial index measurement; established and putative laboratory risk markers; and socioeconomic, psychological, behavioral, and environmental characteristics. Selected baseline components were repeated and additional components such as spirometry, retinal photography, genotyping, cognitive function assessment and, in subsets, abdominal aortic CT, carotid MRI, cardiac MRI tagging for measures of regional myocardial function, were introduced over five subsequent examinations through 2018. Stored blood samples have been assayed for putative biochemical risk factors and stored for case-control studies. DNA has been extracted for study of candidate genes, genome-wide scanning, expression, and other -omics investigations, and lymphocytes were cryopreserved for possible immortalization.
MESA is unique in its composition of four ethnic groups, having a cohort free of clinical CVD at baseline, and having multiple - and in some cases unique - subclinical CVD measures over time in the same individuals. Data collected from a large number and variety of MESA ancillary studies, including major ancillary studies on air pollution, chronic lung disease, genetics, and sleep, further contribute to its uniqueness. For a list of all phenotypic data documentation and protocols, refer to the MESA website: www.mesa-nhlbi.org. The MESA data are available to qualifying investigators directly from the study and also through dbGaP (http://www.ncbi.nlm.nih.gov/gap) and BioLINCC (https://biolincc.nhlbi.nih.gov). A variety of stored biospecimens are also available from the study, including DNA, serum, plasma, and urine.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 45 to 84 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants were recruited from the MESA Study Field Centers.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
CVD
Time frame: 06/18/2025
Rate of Cardiovascular Disease
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jan 2026.
- Derived from this study: PubMed 42770818Momtazmanesh S, Hathaway QA, Bancks MP, Bluemke DA, Barr RG, Post WS, Habes M, Nasrallah I, Heckbert SR, Bryan RN, Luchsinger JA, Wan M, Budoff M, Lima JAC, Hughes TM, Davatzikos C, Demehri S. Deep Learning-derived Bone Mineral Density and Longitudinal White Matter Microstructure and Cognitive Decline: Multi-Ethnic Study of Atherosclerosis. Radiology. 2026 Sep;320(3):e260656. doi: 10.1148/radiol.260656.
- Derived from this study: PubMed 42742379Hathaway QA, Ghotbi E, Pan T, Momtazmanesh S, Klein JG, Allison M, Barbosa EJM Jr, Barr RG, Bluemke DA, Lima JAC, Post W, Tison GH, Ambale-Venkatesh B, Budoff M, Demehri S. Opportunistic Chest CT Paraspinal Muscle Biomarkers to Predict Longitudinal Thoracic Vertebral Bone Mineral Density Loss: Results from MESA. Radiology. 2026 Sep;320(3):e260238. doi: 10.1148/radiol.260238.
- Derived from this study: PubMed 42390348Azimi A, Atlas K, Reeves AP, Zhang C, Wasserthal J, Mirjalili SR, Atlas T, Henschke CI, Yankelevitz DF, Zulueta JJ, Mechanick JI, Branch A, Ma N, Yip R, Fan W, Roy SK, Nasir K, Molloi S, Fayad ZA, McConnell MV, Kakadiaris IA, Abela GS, Vliegenthart R, Maron DJ, Narula J, Williams KA Sr, Shah PK, Budoff MJ, Levy D, Benjamin EJ, Wong ND, Naghavi M. AI-quantified Myosteatosis at CAC CT for Prediction of Atrial Fibrillation and Heart Failure: The Multi-Ethnic Study of Atherosclerosis. Radiol Cardiothorac Imaging. 2026 Aug;8(4):e250214. doi: 10.1148/ryct.250214.
- Derived from this study: PubMed 41609478Azimi A, Atlas K, Reeves AP, Zhang C, Wasserthal J, Mirjalili SR, Atlas T, Henschke CI, Yankelevitz DF, Zulueta JJ, de-Torres JP, Seijo LM, Mechanick JI, Branch A, Ma N, Yip R, Fan W, Roy SK, Nasir K, Molloi S, Fayad ZA, McConnell MV, Kakadiaris IA, Abela GS, Vliegenthart R, Maron DJ, Narula J, Williams KA, Shah PK, Budoff MJ, Levy D, Benjamin EJ, Mehran R, Kloner RA, Wong ND, Naghavi M. Artificial Intelligence-derived Measurements of Myosteatosis from Coronary Artery Calcium CT Scans to Predict COPD: The Multi-Ethnic Study of Atherosclerosis. Radiol Cardiothorac Imaging. 2026 Feb;8(1):e250205. doi: 10.1148/ryct.250205.
- Derived from this study: PubMed 41342680Ghotbi E, Hathaway QA, Bluemke DA, Ibad HA, Shabani M, Akhtarkhavari S, Barr RG, Post WS, Budoff M, Mathur A, Lima JAC, Demehri S. CT-derived Noncardiovascular Calcifications May Improve Coronary Heart Disease Prediction in Chronic Kidney Disease: The Multi-Ethnic Study of Atherosclerosis. Radiol Cardiothorac Imaging. 2025 Dec;7(6):e240546. doi: 10.1148/ryct.240546.
- Derived from this study: PubMed 41027334de Alencar JN, Felicioni SP. Electrocardiographic LVH criteria: Poor diagnostic accuracy even with optimized cutoffs. Insights from MESA study. J Electrocardiol. 2025 Nov-Dec;93:154138. doi: 10.1016/j.jelectrocard.2025.154138. Epub 2025 Sep 26.
- Derived from this study: PubMed 40828040Hoballah M, Chehab O, Abdollahi A, Wu CO, Scarpa B, Post WS, Allen NB, Bluemke DA, Ambale-Venkatesh B, Lima JAC. Left-to-Right Chamber Volume Ratios at Cardiac MRI Predict Cardiac Events: A Multi-Ethnic Study of Atherosclerosis Secondary Analysis. Radiology. 2025 Aug;316(2):e243462. doi: 10.1148/radiol.243462.
- Derived from this study: PubMed 40106977Hao QY, Gao JW, Zeng YH, Zhang SL, Xiong ZC, Li SC, Lin ZW, Yang PZ, Liu PM, Li ZH. Roles of triglyceride-glucose index in aortic valve calcification progression: a prospective and Mendelian randomization analysis. Clin Radiol. 2025 May;84:106860. doi: 10.1016/j.crad.2025.106860. Epub 2025 Feb 21.
- Derived from this study: PubMed 40067103Hathaway QA, Kasaeian A, Pan T, Bluemke DA, Ghotbi E, Klein JG, Ibad HA, Dailing C, Tison GH, Barr RG, Post W, Allison M, Lima JAC, Budoff M, Demehri S. A Deep Learning Model for Three-Dimensional Determination of Whole Thoracic Vertebral Bone Mineral Density from Noncontrast Chest CT: The Multi-Ethnic Study of Atherosclerosis. Radiology. 2025 Mar;314(3):e242133. doi: 10.1148/radiol.242133.
- Derived from this study: PubMed 39977247Chan JSK, Satti DI, Chan RNC, Chevli P, Mehta A, Martin SS, Sharma G, Tse G, Virani SS, Shapiro MD. Visit-to-visit lipid variability, coronary artery calcification, inflammation, and mortality in the Multi-Ethnic Study of Atherosclerosis. Eur J Prev Cardiol. 2025 Sep 22;32(13):1235-1244. doi: 10.1093/eurjpc/zwaf085.
- Derived from this study: PubMed 39909110Amiel PJ, Ambale-Venkatesh B, Wu CO, Matheson M, Ostovaneh MR, Lima JAC, Cox CF. Evaluating Incident Atrial Fibrillation and Incident Heart Failure as Time-varying Covariates for Time-to-Event Analysis Among Adults 55 Years and Older in the Multi-Ethnic Study of Atherosclerosis (MESA). J Card Fail. 2025 Dec;31(12):1809-1818. doi: 10.1016/j.cardfail.2025.01.012. Epub 2025 Feb 3.
- Derived from this study: PubMed 39827737Osmancevic A, Allison M, Miljkovic I, Vella CA, Ouyang P, Trimpou P, Daka B. Exploring the Relationships between Sex Hormones and Abdominal Muscle Area and Radiodensity in Postmenopausal Women: Insights from the Multi-Ethnic Study of Atherosclerosis. Maturitas. 2025 Mar;194:108197. doi: 10.1016/j.maturitas.2025.108197. Epub 2025 Jan 18.
- Click here for the MESA Study web siteLink provided by the sponsor.
- Click here for the MESA Study BioLINCC web siteLink provided by the sponsor.
Related trials for Atherosclerosis
Recruiting
Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With Stable Angina or ACS - A Traditional Feasibility Study
Coronary Arterial Disease (CAD), Plaque
Recruiting
Personalised Multicomponent Exercise Programme in Peripheral Arterial Disease
Peripheral Arterial Disease, Intermittent Claudication
Recruiting
Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension
Atherosclerosis Cardiovascular Disease
Active, not recruitingPhase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Atherosclerotic Cardiovascular Disease, Overweight
Active, not recruitingObservational study
A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events (OPTIMUS RISK - Spain)
Atherosclerotic Cardiovascular Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Robyn McClelland principal investigator
University of Washington
Steven Shea principal investigator
Columbia University
Wendy Post principal investigator
Johns Hopkins University
Questions about this trial
What is this clinical trial studying?
An observational study of Atherosclerosis and Cardiovascular Diseases, run by National Heart, Lung, and Blood Institute (NHLBI).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 21 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
CVD (time frame: 06/18/2025). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00005487, which also lists 81 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2026.